View ValuationBioSyent 将来の成長Future 基準チェック /16BioSyentの収益は成長。EPSは成長すると14.3%年率で予測されます。主要情報n/a収益成長率14.30%EPS成長率Pharmaceuticals 収益成長14.5%収益成長率18.8%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日15 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 21BioSyent Inc. Announces Health Canada Approval of Thyconvi (Levothyroxine Oral Solution)BioSyent Inc. announced that Health Canada has approved Thyconvi (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (TSH) suppression. BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi in Canada. Thyconvi is an oral liquid dosage containing 20 micrograms (mcg) of levothyroxine sodium per millilitre (mL). Thyconvi is indicated for: Hypothyroidism - as a replacement or supplemental therapy in patients of any age with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism of any etiology, in any state (including pregnancy) except transient hypothyroidism during the recovery phase of subacute thyroiditis. Pituitary Thyrotropin (TSH) Suppression - as an adjunct to surgery and radioactive iodine therapy in the management of thyrotropin-dependent well-differentiated papillary or follicular carcinoma of the thyroid. Thyconvi is supplied in a package of two 75 mL bottles without the need for refrigeration. Thyconvi offers broad, convenient dose flexibility for patients who have challenges taking solid doses.お知らせ • May 16BioSyent Inc. Declares Second Quarter 2026 Dividend, Payable on June 15, 2026BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of CAD 0.055 per common share.お知らせ • May 08BioSyent Inc. to Report Q1, 2026 Results on May 14, 2026BioSyent Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026お知らせ • Mar 13BioSyent Inc. to Report Q4, 2025 Results on Mar 19, 2026BioSyent Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026お知らせ • Mar 03BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million.BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc from a group of shareholders for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow, and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million. For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million. Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026. Rory Cattanach of Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc. BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million on February 8, 2026. A cash payment of CAD 22.5 million, of which CAD 0.2 million will be satisfied by granting 12,666 Restricted Share Units to certain Oral Science employees, vesting on the second anniversary of the grant date. Also issued 234,192 common shares valued at CAD 3.0 million, of which 167,635 are under a two-year escrow and 66,557 are under a two-year lock-up, releasing 25% every six months. An additional CAD 2 million cash was paid at closing for excess working capital. The sellers may also receive a contingent earn-out in 2027 based on 2025–2026 performance and royalties until 2033 of up to CAD 6 million.お知らせ • Feb 17BioSyent Inc., Annual General Meeting, May 14, 2026BioSyent Inc., Annual General Meeting, May 14, 2026.お知らせ • Feb 09BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million.BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million. For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million. Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026. Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc.お知らせ • Jan 30BioSyent Inc. Declares Quarterly Dividend for the First Quarter of 2026, Payable on March 13, 2026BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on March 13, 2026, to shareholders of record at the close of business on February 27, 2026. This first quarter 2026 dividend represents a 10% increase from the fourth quarter 2025 dividend of $0.05 per common share.お知らせ • Nov 22BioSyent Declares Fourth Quarter 2025 Dividend, Payable on December 15, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. This fourth quarter 2025 dividend compares with the third quarter 2025 dividend of $0.05 per common share.お知らせ • Nov 14BioSyent Inc. to Report Q3, 2025 Results on Nov 20, 2025BioSyent Inc. announced that they will report Q3, 2025 results After-Market on Nov 20, 2025お知らせ • Aug 22BioSyent Inc. Declares Dividend for Third Quarter of 2025, Payable on September 15, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.05 per common share, payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. This third quarter 2025 dividend compares with the second quarter 2025 dividend of CAD 0.05 per common share.お知らせ • Aug 15BioSyent Inc. to Report Q2, 2025 Results on Aug 21, 2025BioSyent Inc. announced that they will report Q2, 2025 results After-Market on Aug 21, 2025お知らせ • May 16BioSyent Inc. Declares Second Quarter 2025 Dividend, Payable on June 13, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on June 13, 2025, to shareholders of record at the close of business on May 30, 2025. This second quarter 2025 dividend compares with the first quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.お知らせ • May 09BioSyent Inc. to Report Q1, 2025 Results on May 15, 2025BioSyent Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025お知らせ • Mar 07BioSyent Inc. to Report Q4, 2024 Results on Mar 13, 2025BioSyent Inc. announced that they will report Q4, 2024 results After-Market on Mar 13, 2025お知らせ • Mar 05BioSyent Inc., Annual General Meeting, May 15, 2025BioSyent Inc., Annual General Meeting, May 15, 2025. Location: ontario, mississauga Canadaお知らせ • Jan 31BioSyent Inc. Declares First Quarter 2025 Dividend, Payable on March 14, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on March 14, 2025, to shareholders of record at the close of business on February 28, 2025. This first quarter 2025 dividend of $0.05 per common share represents an 11.1% increase from the fourth quarter 2024 dividend of $0.045 per common share.お知らせ • Nov 20December 16, 2024 Declares Fourth Quarter 2024 Dividend, Payable on December 16, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. This fourth quarter 2024 dividend compares with the third quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.お知らせ • Nov 14BioSyent Inc. to Report Q3, 2024 Results on Nov 20, 2024BioSyent Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 20, 2024お知らせ • Aug 27Biosyent Inc Declares Dividend for the Third Quarter of 2024, Payable on September 15, 2024BioSyent Inc. announced that its Board of Directors have declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on September 15, 2024, to shareholders of record at the close of business on September 4, 2024. This third quarter 2024 dividend compares with the second quarter 2024 dividend of $0.045 per common share.お知らせ • May 18BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024. This second quarter 2024 dividend compares with the first quarter 2024 dividend of $0.045 per common share.お知らせ • May 11BioSyent Inc. to Report Q1, 2024 Results on May 16, 2024BioSyent Inc. announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on May 16, 2024お知らせ • Mar 19BioSyent Inc., Annual General Meeting, May 16, 2024BioSyent Inc., Annual General Meeting, May 16, 2024.お知らせ • Mar 07BioSyent Inc. to Report Q4, 2023 Results on Mar 13, 2024BioSyent Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024お知らせ • Feb 07BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. This first quarter 2024 dividend of $0.045 per common share represents a 12.5% increase from the fourth quarter 2023 dividend of $0.040 per common share.お知らせ • Nov 17BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. This fourth quarter 2023 dividend compares with the third quarter 2023 dividend of $0.04 per common share.お知らせ • Nov 10BioSyent Inc. to Report Q3, 2023 Results on Nov 16, 2023BioSyent Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 16, 2023お知らせ • Aug 23BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on September 15, 2023, to shareholders of record at the close of business on August 31, 2023. This third quarter 2023 dividend compares with the second quarter 2023 dividend of $0.04 per common share.お知らせ • Aug 16BioSyent Inc. to Report Q2, 2023 Results on Aug 22, 2023BioSyent Inc. announced that they will report Q2, 2023 results After-Market on Aug 22, 2023お知らせ • May 26BioSyent Inc. Declares Second Quarter 2023 Dividend, Payable on June 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023. This second quarter 2023 dividend compares with the first quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.お知らせ • May 19BioSyent Inc. to Report Q1, 2023 Results on May 26, 2023BioSyent Inc. announced that they will report Q1, 2023 results at 8:00 AM, US Eastern Standard Time on May 26, 2023お知らせ • Feb 02BioSyent Inc. Declares Dividend for the First Quarter 2023, Payable on March 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023. This first quarter 2023 dividend compares with the fourth quarter 2022 dividend of $0.04 per common share.業績と収益の成長予測OTCPK:BIOY.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202884N/AN/AN/A112/31/202779N/AN/AN/A112/31/202669N/AN/AN/A13/31/20264691212N/A12/31/202543999N/A9/30/202542988N/A6/30/2025408712N/A3/31/202538827N/A12/31/202435749N/A9/30/202435727N/A6/30/202434723N/A3/31/202433777N/A12/31/202332655N/A9/30/202331667N/A6/30/202329555N/A3/31/202327534N/A12/31/202228545N/A9/30/202228645N/A6/30/202228666N/A3/31/202228655N/A12/31/202129655N/A9/30/202127555N/A6/30/202126444N/A3/31/202124456N/A12/31/202022477N/A9/30/2020224108N/A6/30/202023567N/A3/31/202023545N/A12/31/2019214N/A4N/A9/30/2019225N/A4N/A6/30/2019215N/A5N/A3/31/2019226N/A6N/A12/31/2018226N/A6N/A9/30/2018225N/A7N/A6/30/2018226N/A7N/A3/31/2018215N/A7N/A12/31/2017215N/A7N/A9/30/2017205N/A6N/A6/30/2017195N/A5N/A3/31/2017184N/A5N/A12/31/2016184N/A4N/A9/30/2016174N/A3N/A6/30/2016174N/A4N/A3/31/2016164N/A4N/A12/31/2015154N/A3N/A9/30/2015154N/A3N/A6/30/2015144N/A3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BIOY.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BIOY.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BIOY.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BIOY.Fの収益 ( 18.8% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: BIOY.Fの収益 ( 18.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BIOY.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:08終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioSyent Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Tania Armstrong-WhitworthATB Cormark Historical (Cormark Securities)David MartinBloom Burton & Co.Scott CurtisCantor Fitzgerald Canada Corporation1 その他のアナリストを表示
お知らせ • May 21BioSyent Inc. Announces Health Canada Approval of Thyconvi (Levothyroxine Oral Solution)BioSyent Inc. announced that Health Canada has approved Thyconvi (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (TSH) suppression. BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi in Canada. Thyconvi is an oral liquid dosage containing 20 micrograms (mcg) of levothyroxine sodium per millilitre (mL). Thyconvi is indicated for: Hypothyroidism - as a replacement or supplemental therapy in patients of any age with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism of any etiology, in any state (including pregnancy) except transient hypothyroidism during the recovery phase of subacute thyroiditis. Pituitary Thyrotropin (TSH) Suppression - as an adjunct to surgery and radioactive iodine therapy in the management of thyrotropin-dependent well-differentiated papillary or follicular carcinoma of the thyroid. Thyconvi is supplied in a package of two 75 mL bottles without the need for refrigeration. Thyconvi offers broad, convenient dose flexibility for patients who have challenges taking solid doses.
お知らせ • May 16BioSyent Inc. Declares Second Quarter 2026 Dividend, Payable on June 15, 2026BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.055 per common share, payable in Canadian Dollars on June 15, 2026, to shareholders of record at the close of business on May 29, 2026. This second quarter 2026 dividend compares to a first quarter dividend of CAD 0.055 per common share.
お知らせ • May 08BioSyent Inc. to Report Q1, 2026 Results on May 14, 2026BioSyent Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026
お知らせ • Mar 13BioSyent Inc. to Report Q4, 2025 Results on Mar 19, 2026BioSyent Inc. announced that they will report Q4, 2025 results After-Market on Mar 19, 2026
お知らせ • Mar 03BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million.BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc from a group of shareholders for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow, and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million. For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million. Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026. Rory Cattanach of Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc. BioSyent Inc. (TSXV:RX) completed the acquisition of Oral Science Inc from a group of shareholders for CAD 33.5 million on February 8, 2026. A cash payment of CAD 22.5 million, of which CAD 0.2 million will be satisfied by granting 12,666 Restricted Share Units to certain Oral Science employees, vesting on the second anniversary of the grant date. Also issued 234,192 common shares valued at CAD 3.0 million, of which 167,635 are under a two-year escrow and 66,557 are under a two-year lock-up, releasing 25% every six months. An additional CAD 2 million cash was paid at closing for excess working capital. The sellers may also receive a contingent earn-out in 2027 based on 2025–2026 performance and royalties until 2033 of up to CAD 6 million.
お知らせ • Feb 17BioSyent Inc., Annual General Meeting, May 14, 2026BioSyent Inc., Annual General Meeting, May 14, 2026.
お知らせ • Feb 09BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million.BioSyent Inc. (TSXV:RX) entered into a Share Purchase Agreement to acquire Oral Science Inc for CAD 31.5 million on February 8, 2026. The consideration consists of CAD 22.5 million of cash and 234,192 BioSyent common shares. A portion of the Consideration Shares will be subject to a two-year escrow and the balance will be subject to a two-year lock-up, with 25% of the locked-up shares released every six months. The purchase price is inclusive of a CAD 6.3 million net working capital requirement on closing. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of CAD 6 million. The transaction will be financed through liquid cash with CAD 16.5 million and senior Secured Demand Term Loan with RBC Royal Bank of CAD 6 million. For the period ending September 30, 2025, Oral Science Inc. reported total revenue of CAD 30 million and EBITDA of CAD 4 million. Subject to the satisfaction of customary closing conditions and BioSyent’s receipt of certain agreements, consents and regulatory approvals, the transaction is expected to close before the end of February 2026. The acquisition is expected to be accretive, with incremental profit and cash flows in 2026. Wildeboer Dellelce LLP acted as legal advisor for BioSyent Inc. KPMG Inc. acted as financial advisor for BioSyent Inc.
お知らせ • Jan 30BioSyent Inc. Declares Quarterly Dividend for the First Quarter of 2026, Payable on March 13, 2026BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on March 13, 2026, to shareholders of record at the close of business on February 27, 2026. This first quarter 2026 dividend represents a 10% increase from the fourth quarter 2025 dividend of $0.05 per common share.
お知らせ • Nov 22BioSyent Declares Fourth Quarter 2025 Dividend, Payable on December 15, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. This fourth quarter 2025 dividend compares with the third quarter 2025 dividend of $0.05 per common share.
お知らせ • Nov 14BioSyent Inc. to Report Q3, 2025 Results on Nov 20, 2025BioSyent Inc. announced that they will report Q3, 2025 results After-Market on Nov 20, 2025
お知らせ • Aug 22BioSyent Inc. Declares Dividend for Third Quarter of 2025, Payable on September 15, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of CAD 0.05 per common share, payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. This third quarter 2025 dividend compares with the second quarter 2025 dividend of CAD 0.05 per common share.
お知らせ • Aug 15BioSyent Inc. to Report Q2, 2025 Results on Aug 21, 2025BioSyent Inc. announced that they will report Q2, 2025 results After-Market on Aug 21, 2025
お知らせ • May 16BioSyent Inc. Declares Second Quarter 2025 Dividend, Payable on June 13, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on June 13, 2025, to shareholders of record at the close of business on May 30, 2025. This second quarter 2025 dividend compares with the first quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
お知らせ • May 09BioSyent Inc. to Report Q1, 2025 Results on May 15, 2025BioSyent Inc. announced that they will report Q1, 2025 results After-Market on May 15, 2025
お知らせ • Mar 07BioSyent Inc. to Report Q4, 2024 Results on Mar 13, 2025BioSyent Inc. announced that they will report Q4, 2024 results After-Market on Mar 13, 2025
お知らせ • Mar 05BioSyent Inc., Annual General Meeting, May 15, 2025BioSyent Inc., Annual General Meeting, May 15, 2025. Location: ontario, mississauga Canada
お知らせ • Jan 31BioSyent Inc. Declares First Quarter 2025 Dividend, Payable on March 14, 2025BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on March 14, 2025, to shareholders of record at the close of business on February 28, 2025. This first quarter 2025 dividend of $0.05 per common share represents an 11.1% increase from the fourth quarter 2024 dividend of $0.045 per common share.
お知らせ • Nov 20December 16, 2024 Declares Fourth Quarter 2024 Dividend, Payable on December 16, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. This fourth quarter 2024 dividend compares with the third quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
お知らせ • Nov 14BioSyent Inc. to Report Q3, 2024 Results on Nov 20, 2024BioSyent Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 20, 2024
お知らせ • Aug 27Biosyent Inc Declares Dividend for the Third Quarter of 2024, Payable on September 15, 2024BioSyent Inc. announced that its Board of Directors have declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on September 15, 2024, to shareholders of record at the close of business on September 4, 2024. This third quarter 2024 dividend compares with the second quarter 2024 dividend of $0.045 per common share.
お知らせ • May 18BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on June 15, 2024, to shareholders of record at the close of business on May 31, 2024. This second quarter 2024 dividend compares with the first quarter 2024 dividend of $0.045 per common share.
お知らせ • May 11BioSyent Inc. to Report Q1, 2024 Results on May 16, 2024BioSyent Inc. announced that they will report Q1, 2024 results at 4:00 PM, US Eastern Standard Time on May 16, 2024
お知らせ • Mar 19BioSyent Inc., Annual General Meeting, May 16, 2024BioSyent Inc., Annual General Meeting, May 16, 2024.
お知らせ • Mar 07BioSyent Inc. to Report Q4, 2023 Results on Mar 13, 2024BioSyent Inc. announced that they will report Q4, 2023 results After-Market on Mar 13, 2024
お知らせ • Feb 07BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on March 15, 2024, to shareholders of record at the close of business on February 29, 2024. This first quarter 2024 dividend of $0.045 per common share represents a 12.5% increase from the fourth quarter 2023 dividend of $0.040 per common share.
お知らせ • Nov 17BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on December 15, 2023, to shareholders of record at the close of business on November 30, 2023. This fourth quarter 2023 dividend compares with the third quarter 2023 dividend of $0.04 per common share.
お知らせ • Nov 10BioSyent Inc. to Report Q3, 2023 Results on Nov 16, 2023BioSyent Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 16, 2023
お知らせ • Aug 23BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on September 15, 2023, to shareholders of record at the close of business on August 31, 2023. This third quarter 2023 dividend compares with the second quarter 2023 dividend of $0.04 per common share.
お知らせ • Aug 16BioSyent Inc. to Report Q2, 2023 Results on Aug 22, 2023BioSyent Inc. announced that they will report Q2, 2023 results After-Market on Aug 22, 2023
お知らせ • May 26BioSyent Inc. Declares Second Quarter 2023 Dividend, Payable on June 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023. This second quarter 2023 dividend compares with the first quarter 2023 dividend of $0.04 per common share. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
お知らせ • May 19BioSyent Inc. to Report Q1, 2023 Results on May 26, 2023BioSyent Inc. announced that they will report Q1, 2023 results at 8:00 AM, US Eastern Standard Time on May 26, 2023
お知らせ • Feb 02BioSyent Inc. Declares Dividend for the First Quarter 2023, Payable on March 15, 2023BioSyent Inc. announced that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023. This first quarter 2023 dividend compares with the fourth quarter 2022 dividend of $0.04 per common share.